• Explore /
  • Poster
  • / Open-label, phase I/randomized, phase II trial of the triple angiokinase inhibitor, nintedanib, versus sorafenib in previously untreated patients with advanced hepatocellular carcinoma (HCC).

Open-label, phase I/randomized, phase II trial of the triple angiokinase inhibitor, nintedanib, versus sorafenib in previously untreated patients with advanced hepatocellular carcinoma (HCC).

Abstract Poster

Authors

null

Daniel H. Palmer

Liverpool Cancer Research UK Centre, University of Liverpool, Liverpool, United Kingdom

Daniel H. Palmer , Markus Peck-Radosavljevic , Yuk Ting Ma , Janet Graham , Laetitia Fartoux , Richard Hubner , Arsene Bienvenu Loembe , Matus Studeny , Julia Hocke , Tim Meyer

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2013 ASCO Annual Meeting

Session Type

Poster Session

Session Title

Gastrointestinal (Noncolorectal) Cancer

Track

Gastrointestinal Cancer—Gastroesophageal, Pancreatic, and Hepatobiliary

Sub Track

Hepatobiliary Cancer

Clinical Trial Registration Number

NCT01004003

Citation

J Clin Oncol 31, 2013 (suppl; abstr TPS4160)

DOI

10.1200/jco.2013.31.15_suppl.tps4160

Abstract #

TPS4160

Poster Bd #

33F

Abstract Disclosures

Similar Posters

First Author: Ann-Lii Cheng

First Author: Tim Meyer

First Author: Tudor-Eliade Ciuleanu

First Author: Arndt Vogel